Chimeric monoclonal antibody that binds and neutralizes soluble and transmembrane tumor necrosis factor α (TNFα). Consists of constant regions of human (Hu)IgG1κ coupled to Fv region of a high-affinity neutralizing murine anti-HuTNFα antibody (A2). Prepn: J. Le et al., WO 9216553 (1992 to New York Univ.; Centocor); D. M. Knight et al., Mol. Immunol. 30, 1443 (1993). Pharmacology: S. A. Siegel et al., Cytokine 7, 15 (1995). Mechanism of action: B. J. Scallon et al., ibid. 251. Clinical study in rheumatoid arthritis: R. Maini et al., Lancet 354, 1932 (1999); in psoriasis: U. Chaudhari et al., ibid. 357, 1842 (2001); in Crohn's disease: B. E. Sands et al., N. Engl. J. Med. 350, 876 (2004). Review of use in early rheumatoid arthritis: R. C. Geletka, E. W. St. Clair, Expert Opin. Biol. Ther. 5, 405-417 (2005); of use in Crohn's disease: M. Bewtra, G. R. Lichtenstein, ibid., 589-599 (2005).
Anti-inflammatory; antipsoriatic.
Anti-inflammatory (Biological Response Modifier); Anti-inflammatory (Gastrointestinal); Antipsoriatic